Stock Comparison

LLY vs TWST

Eli Lilly and Co vs Twist Bioscience Corp

The Verdict

TWST takes this one.

LLY

Eli Lilly and Co

0.5

out of 10

Distressed

Winner

TWST

Twist Bioscience Corp

7.0

out of 10

Solid Pick

Head-to-Head

$965.0B

Market Cap

$4.2B

52.6

P/E Ratio

14.7

N/A

Profit Margin

-19.9%

N/A

Return on Equity

-17.5%

N/A

Debt-to-Equity

0.5

Moderate

Overall Risk

Aggressive

0.5

DVR Score

7.0

The Deep Dive

LLY0.5/10

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Full LLY Analysis

TWST7.0/10

Twist Bioscience maintains its high-risk, high-reward profile with compelling 10x growth potential, driven by its unique silicon-based DNA synthesis platform and strategic entry into DNA data storage. Q2 FY26 results confirmed strong revenue growth and expanded clonal gene offerings, reinforcing its market opportunity and technological moat. However, the reported EPS miss for Q2 FY26 and ongoing i...

Full TWST Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.